How E. coli adapts to non-lethal rifampicin stress

Antibiotics can change bacterial behavior even when they do not kill the cells outright. The drug rifampicin blocks transcription and, at non-lethal concentrations, perturbs bacteria in ways that push them to adjust their physiology to avoid death. Those short-term adjustments can be followed by beneficial mutations that lock in survival advantages. To uncover how these adjustments are controlled across the genome, André S. Ribeiro and colleagues studied susceptible Escherichia coli cells exposed to non-lethal rifampicin in a time-resolved, genome-wide experiment. Instead of looking at single genes, they tracked how the entire transcriptome changed over time after exposure. The team wanted to identify the regulatory mechanisms that shape which genes change, how strongly they change, and how those changes evolve during and after the stress. By focusing on the dynamic response rather than only endpoints, the work aimed to reveal both immediate coping strategies and longer-term patterns that could set the stage for resistance.

The results showed a dynamic reshaping of gene activity: the transcriptome first diverged widely from untreated control cells and later partially realigned toward the original state. The study traced that behavior to a set of concrete mechanisms. Changes in RNAP and Gyrase levels, differences in promoter sequences, and rewiring of the transcription factor network all influenced which genes were turned up or down. Physical features such as intergenic distance and sensitivity to DNA supercoiling buildup mattered too, as did σ factor specificity, the alarmone (p)ppGpp, and a few global regulators. To test whether these patterns were specific to E. coli or more general, the researchers compared their findings with the distant pathogen Mycobacterium tuberculosis. In both species, adjacent genes on the DNA showed similar response strengths, and orthologous genes across species had correlated response magnitudes. Additionally, E. coli orthologs were enriched among the mechanisms identified as influential, supporting the idea of shared, likely beneficial phenotypic adaptations.

Taken together, these observations indicate that the large-scale dynamics of the transcriptome under rifampicin are not random but are shaped by the architecture of the gene regulatory network. In practical terms, E. coli—and likely other bacteria—use a set of biochemical and genomic features to mount coordinated responses by specific cohorts of genes when faced with non-lethal rifampicin stress. Those coordinated responses enhance short-term survivability, which the authors argue can create conditions favorable for the later emergence of resistance through beneficial mutations. By revealing the mechanistic players—RNAP, Gyrase, promoter features, transcription factors, σ factors, (p)ppGpp, DNA supercoiling sensitivity, intergenic distance, and global regulators—this work points to why low-level antibiotic exposure can lead to persistent, adaptive phenotypes that may ultimately undermine treatment effectiveness.